Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 3/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720391 | 1.00 | USP2 (0.68) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL8987523 | 0.87 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL27572380 | 0.82 | — | — | |
| SCHEMBL10782117 | 0.82 | — | — | |
| SCHEMBL11122838 | 0.82 | — | — | |
| Mannitol SCHEMBL1504919 | 0.82 | LMNA (0.69) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL28204430 | 0.82 | LMNA (0.69) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| Glucosaminic Acid SCHEMBL5290846 | 0.81 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| Glucosaminic Acid SCHEMBL13010965 | 0.81 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| Glucosaminic Acid SCHEMBL396940 | 0.81 | USP2 (1.00) | USP2SLCO1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116802169-A | Solid binder | 洛科威有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116724014-A | Stadium with shock pad | 洛科威有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-116710522-A | Mineral wool product with low chloride content | 洛科威有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116710419-A | Acoustic product | 洛科威有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116710420-A | High temperature low emission mineral wool product | 洛科威有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116685566-A | Facade system and insulating element for a facade system | 洛科威有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116670098-A | Drainage method | 洛科威有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116670099-A | Mineral fiber product | 洛科威有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116670100-A | Roof system | 洛科威有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116648441-A | Roof system and insulation element for flat or pitched roof | 洛科威有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-110028533-A | A kind of method and application of the refining amino glucosamine salt hydrochlorate from microbial fermentation solution | 浙江中医药大学 | 2019-07-19 | — | — | CN | claimed |
| EP-2624821-B1 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES | EAGLEPHARMA PTY LTD (AU) | 2018-06-27 | — | — | EP | claimed |
| US-20170304351-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES | EAGLEPHARMA PTY LTD (AU) | 2017-10-26 | — | — | US | claimed |
| CN-104788510-A | Method for extracting glucosamine from self-fermentation liquid | JIANGSU SEL BIOCHEM CO LTD | 2015-07-22 | — | — | CN | claimed |
| CN-102977158-B | Method for preparing glucosamine hydrochloride by use of pleuromutilin waste thalli | JIANGSU SEL BIOCHEM CO LTD | 2015-01-28 | — | — | CN | claimed |
| CN-102977158-A | Method for preparing glucosamine hydrochloride by use of pleuromutilin waste thalli | JIANGSU SEL BIOCHEMISTRY CO LTD | 2013-03-20 | — | — | CN | claimed |
| CN-102408458-A | Production process for refining glucosamine hydrochloride by membrane separation method | NANTONG FOREIGN TRADE MEDICAL HEALTH CARE PRODUCTS CO LTD | 2012-04-11 | — | — | CN | claimed |
| US-7855188-B2 | Quarternized amino glucosamine compound for exerting anticancer effect | PUKYONG NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2010-12-21 | — | — | US | claimed |
| US-20090176978-A1 | QUARTERNIZED AMINO GLUCOSAMINE COMPOUND FOR EXERTING ANTICANCER EFFECT | PUKYONG NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2009-07-09 | — | — | US | claimed |
| WO-2008007825-A1 | QUARTERNIZED AMINO GLUCOSAMINE COMPOUND FOR EXERTING ANTICANCER EFFECT | PUKYONG NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2008-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176978-A1 | QUARTERNIZED AMINO GLUCOSAMINE COMPOUND FOR EXERTING ANTICANCER EFFECT | GLUL, OGT, GLMN | USP2 989/4885SLCO1B1 3981/4885LMNA 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.